

**genedrive plc**  
**("genedrive" or the "Company")**

**Equity Prepayment Facility drawdown**

genedrive plc (LSE: GDR), the point of care molecular diagnostics company, today announces a further scheduled £300,000 draw down under the terms of the £5m Equity Prepayment Facility, which was previously announced by the Company on 31 March 2023. Investors have been granted 724,997 warrants equal to 40% of this drawdown divided by the Reference Price of 16.55178 pence. The exercise price of the warrants payable to the Company will be 140% of the Reference Price equating to 23.172492 pence.

Capitalised terms in this announcement shall, unless the context demands otherwise, bear the meanings given to such terms in the announcement of the Facility made via RNS on 31 March 2023.

**For further information, please contact:**

<b>genedrive plc</b> David Budd (CEO) / Russ Shaw (CFO)	+44 (0) 161 989 0245
<b>Peel Hunt LLP - Nominated Adviser, Joint Broker</b> James Steel / Oliver Duckworth	+44 (0) 20 7148 8900
<b>finnCap Ltd - Joint Broker</b> Geoff Nash / George Dollemore	+44 (0) 20 7220 0500
<b>Walbrook PR - Financial PR &amp; IR Adviser</b> Paul McManus / Anna Dunphy	+44 (0) 20 7933 8780 Or <a href="mailto:Genedrive@walbrookpr.com">Genedrive@walbrookpr.com</a>

**About genedrive plc** (<http://www.genedriveplc.com>)

genedrive plc is a molecular diagnostics company developing and commercialising a low cost, rapid, versatile, simple to use and robust point of need molecular diagnostics platform for the diagnosis of infectious diseases and for use in patient stratification (genotyping), pathogen detection and other indications. The company are currently developing a genetic test for CYP2C19 metaboliser status.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [rs@seg.com](mailto:rs@seg.com) or visit [www.rs.com](http://www.rs.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

MSCUPUUGMUPWURA